First Time Loading...
P

Pulike Biological Engineering Inc
SSE:603566

Watchlist Manager
Pulike Biological Engineering Inc
SSE:603566
Watchlist
Price: 23.18 CNY 10.01% Market Closed
Updated: May 18, 2024
Section:
 

Relative Value

The Relative Value of one Pulike Biological Engineering Inc stock under the Base Case scenario is 29.06 CNY. Compared to the current market price of 23.18 CNY, Pulike Biological Engineering Inc is Undervalued by 20%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

Relative Value
Base Case
29.06 CNY
Undervaluation 20%
Relative Value
Price
P
Worst Case
Base Case
Best Case

Valuation Multiples

6
P/S
P/S
Price to Sales
6
vs History
84
vs Industry
23
Median 3Y
6.3
Median 5Y
7.1
Industry
2.5
Forward
5.8
More Details
36.4
P/E
P/E
Price to Earnings
36.4
vs History
65
vs Industry
14
Median 3Y
33.5
Median 5Y
38.1
Industry
23.5
Forward
34
More Details
32.4
P/OCF
P/OCF
Price to OCF
32.4
vs History
71
vs Industry
14
Median 3Y
32.3
Median 5Y
34.5
Industry
17.4
More Details
Negative
P/FCFE
P/FCFE
Price to FCFE
N/A
vs History
vs Industry
Median 3Y
-47.5
Median 5Y
65
Industry
24.3
More Details
2.9
P/B
P/B
Price to Book Value
2.9
vs History
84
vs Industry
27
Median 3Y
3.4
Median 5Y
3.5
Industry
2.1
More Details
5.4
EV/S
EV/S
Enterprise Value to Sales
5.4
vs History
88
vs Industry
23
Median 3Y
5.9
Median 5Y
6.6
Industry
2.6
Forward
5.2
More Details
8.9
EV/GP
EV/GP
Enterprise Value to Gross Profit
8.9
vs History
82
vs Industry
25
Median 3Y
9.4
Median 5Y
10.5
Industry
5.3
More Details
29.7
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
29.7
vs History
77
vs Industry
12
Median 3Y
29
Median 5Y
35.5
Industry
13.7
Forward
19.4
More Details
29.7
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
29.7
vs History
77
vs Industry
15
Median 3Y
29
Median 5Y
35.5
Industry
17.4
Forward
31
More Details
29.2
EV/OCF
EV/OCF
Enterprise Value to OCF
29.2
vs History
74
vs Industry
16
Median 3Y
30.4
Median 5Y
32.6
Industry
16.2
More Details
Negative
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
N/A
vs History
vs Industry
Median 3Y
-44.8
Median 5Y
59.6
Industry
18.6
More Details
3
EV/IC
EV/IC
Enterprise Value to IC
3
vs History
87
vs Industry
27
Median 3Y
3.5
Median 5Y
3.7
Industry
1.9
More Details

Multiples Across Competitors

Competitors Multiples
Pulike Biological Engineering Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
CN
Pulike Biological Engineering Inc
SSE:603566
8B CNY 6 36.4 29.7 29.7
JP
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
776 550.9T JPY 4 211 733 -5 347 888.9 -5 459 134.4 -5 046 864.6
US
Eli Lilly and Co
NYSE:LLY
731.8B USD 20.4 119.2 58.4 66.4
DK
Novo Nordisk A/S
CSE:NOVO B
4T DKK 16.5 45.1 33.6 36.9
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
372.2B USD 4.3 9.7 11.9 15.6
US
Merck & Co Inc
NYSE:MRK
332.3B USD 5.4 144.1 35.9 58.5
UK
AstraZeneca PLC
LSE:AZN
187.7B GBP 5 37.6 174.5 278.4
CH
Roche Holding AG
SIX:ROG
189B CHF 3.2 16.4 9.3 11
CH
Novartis AG
SIX:NOVN
182.7B CHF 3.4 11.5 8.7 12.7
US
Pfizer Inc
NYSE:PFE
161.7B USD 2.9 -523.3 12.9 20.6
P/E Multiple
Earnings Growth
CN
P
Pulike Biological Engineering Inc
SSE:603566
Average P/E: 52.5
36.4
122%
JP
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
Negative Multiple: -5 347 888.9 N/A
US
Eli Lilly and Co
NYSE:LLY
119.2
346%
DK
Novo Nordisk A/S
CSE:NOVO B
45.1
84%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A
US
Johnson & Johnson
NYSE:JNJ
9.7
-20%
US
Merck & Co Inc
NYSE:MRK
144.1
7 454%
UK
AstraZeneca PLC
LSE:AZN
37.6
168%
CH
Roche Holding AG
SIX:ROG
16.4
26%
CH
Novartis AG
SIX:NOVN
11.5
15%
US
Pfizer Inc
NYSE:PFE
Negative Multiple: -523.3
680%

See Also

Summary
Intrinsic value, competitors valuation, and company profile.
DCF Valuation
Stock valuation using Discount Cash Flow valuation method.
Relative Valuation
Stock valuation using valuation multiples.
Wall Street Estimates
Price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
Stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
ALPHA SPREAD
Join more than 138,200+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.